Insider Selling: Surrozen, Inc. (NASDAQ:SRZN) VP Sells 843 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $17.37, for a total transaction of $14,642.91. Following the completion of the sale, the vice president now owns 13,345 shares in the company, valued at approximately $231,802.65. The trade was a 5.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Surrozen Trading Down 16.4 %

SRZN stock traded down $2.79 during midday trading on Monday, reaching $14.23. 197,851 shares of the stock were exchanged, compared to its average volume of 168,984. Surrozen, Inc. has a 52 week low of $6.00 and a 52 week high of $18.17. The company has a fifty day moving average price of $10.92 and a 200 day moving average price of $9.90.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($2.77) by $2.33. The firm had revenue of $10.00 million for the quarter. As a group, sell-side analysts predict that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRZN. Stonepine Capital Management LLC lifted its holdings in shares of Surrozen by 66.5% during the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $1,318,000 after purchasing an additional 43,916 shares during the period. Nantahala Capital Management LLC bought a new position in Surrozen during the 2nd quarter worth $2,050,000. CVI Holdings LLC bought a new position in Surrozen during the 2nd quarter worth $711,000. Finally, Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter worth about $2,080,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Friday.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.